Related Experiment Video
Updated: Jun 25, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Nonstructured treatment interruptions among injection drug users in Baltimore, MD
Ravi Kavasery1, Noya Galai, Jacquie Astemborski
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Insights
Non-structured treatment interruptions (NTIs) were common among injection drug users (IDUs) on highly active antiretroviral therapy (HAART). Active drug use and disrupted healthcare were linked to NTIs, highlighting the need for integrated HIV and substance abuse treatment.
Area of Science:
- Public Health
- Infectious Diseases
- Addiction Medicine
Background:
- Characterizing highly active antiretroviral therapy (HAART) use patterns.
- Identifying predictors of non-structured treatment interruptions (NTIs) among injection drug users (IDUs).
Purpose of the Study:
- To analyze HAART adherence and NTI predictors in Baltimore IDUs.
- To understand factors influencing HAART restart after NTIs.
Main Methods:
- Studied 335 IDUs initiating HAART (1996-2006).
- Defined NTIs as 6-month intervals without HAART.
- Used Cox regression to analyze NTI predictors and HAART restart.
Main Results:
- 78% of IDUs experienced at least one NTI.
- NTIs were more common in women, those with detectable HIV RNA, and daily injectors.
- Younger age, active injection, incarceration, and alcohol use predicted NTI timing and duration.
- Recent outpatient visits and cessation of injection predicted HAART restart.
Conclusions:
- NTIs are prevalent in IDUs, associated with active drug use and healthcare disruption.
- Integrated HIV care and substance abuse treatment are crucial for improving HAART outcomes in this population.
Background:
We characterized patterns of highly active antiretroviral therapy (HAART) use and predictors of nonstructured treatment interruptions (NTIs) among injection drug users (IDUs) in Baltimore, MD.
Methods:
Three hundred thirty-five IDUs who initiated HAART from 1996 to 2006 were studied. NTIs were defined as any subsequent 6-month interval where HAART was not reported. Predictors of the first NTI and subsequent restart of HAART were examined using Cox regression.
Results:
Two hundred sixty (78%) reported > or =1 NTI. Of 215 with > or =1 follow-up visit after the NTI, 44 (20%) never restarted HAART, 62 (29%) restarted and remained on HAART, and 109 (51%) reported multiple NTIs. NTIs were less likely among those who initiated HAART in later calendar years and had a recent outpatient visit and more likely among women, persons with detectable HIV RNA at the prior visit, and those who reported injecting daily. Among those with NTIs, interuptions occurred earlier in persons who were younger, who did not have a prior AIDS diagnosis, and who were actively injecting; NTIs lasted longer in persons who had higher HIV RNA levels, in persons who were incarcerated, and in persons drinking alcohol. A recent outpatient visit and not actively injecting were associated with restarting HAART.
Conclusions:
NTIs were common in this population and occurred most frequently in the setting of active drug use and disruption of health care. Effective linkages between primary care for HIV and substance abuse treatment may improve HAART outcomes in this population.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Oral Drug Delivery Systems: Continuous-Release Systems

